

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016934 A1

(51) International Patent Classification⁷: **C07D 498/22**,
513/22, A61K 49/00

(21) International Application Number:
PCT/EP2004/009225

(22) International Filing Date: 17 August 2004 (17.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/495,921 18 August 2003 (18.08.2003) US

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AUBERSON, Yves** [CH/CH]; Maiengasse 4, CH-4123 Allschwil (CH). **GREMLICH, Hans-Ulrich** [CH/CH]; Buchenrain 3, CH-4106 Therwil (CH). **HINTERSTEINER, Martin**

[AT/AT]; Erzbischofgasse 32/16, A-1130 Wien (AT). **KINZY, Willy** [DE/DE]; Talweg 28A, 79540 Lörrach (DE). **KNEUER, Rainer** [DE/DE]; Königsbergerstrasse 3, 79539 Lörrach (DE).


(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: 3H-PHENOXAZINE DERIVATIVES SUITABLE AS NEAR-INFRARED IMAGING AGENTS, PREPARATION AND USE THEREOF



(I)

(57) Abstract: The present invention provides compounds of formula (I) wherein X and Y represent CH, CH₂ or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH₂; m and o represent independently of each other 0 or 1, with the proviso that if m is 0 then the dotted line between Y and the neighboring C atom represents a bond and Y is CH or a trivalent heteroatom, if m is 1 then the dotted line between Y and the neighboring C atom is absent and Y is CH₂ or a divalent heteroatom, if o is 0 then the dotted line between X and the neighboring C atom represents a bond and

X is CH or a trivalent heteroatom, if o is 1 then the dotted line between X and the neighboring C atom is absent and X is CH₂ or a divalent heteroatom; A represents (CH₂CR₉)_p and Q represents (CR₉R₁₀)_n; n and p represent independently of each other 0 or 1; R₆, R₇, R₁₃ and R₁₄ denote independently of each other hydrogen, halogen, (C₁₋₄)alkyl, (C₁₋₄)alkylSO₂, SO₃H, carboxy, (C₁₋₄)alkoxy carbonyl, (C₁₋₄)alkoxy, OH or NR₁₅R₁₆; R₁, R₂, R₃, R₄, R₉, R₁₀, R₁₁ and R₁₂ denote independently of each other hydrogen, (C₁₋₄)alkyl, carboxy, (C₁₋₄)alkoxy carbonyl or (C₁₋₄)alkoxy, or, when X is CH or CH₂ then R₁ and R₂ can also be OH or NR₁₅R₁₆, or when Y is CH or CH₂ then R₁₁, R₁₂ can also be OH or NR₁₅R₁₆; R₅, R₈, R₁₅ and R₁₆ are independently of each other hydrogen, (C₁₋₄)alkyl, (C₁₋₄)alkoxy, R₁₇O-C(O)-(C₁₋₄)alkyl or (reactive group)-(C₁₋₄)alkyl; and R₁₇ represents hydrogen or (C₁₋₄)alkyl; compositions comprising such compounds, a process for the production of such compounds of formula (I), a method of labeling target structures, especially amyloid plaques, in the brain, a method for identifying Alzheimer's disease, use of a compound of formula I as a near-infrared imaging agent and a conjugate comprising a compound of formula (I) covalently linked to a biomolecule through a reactive group.



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.